Dashboard
1
Poor Management Efficiency with a low ROCE of 3.26%
- The company has been able to generate a Return on Capital Employed (avg) of 3.26% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -20.24% and Operating profit at -196.08% over the last 5 years
3
Flat results in Mar 25
4
Risky -
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,032 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.03
-18.37%
5.49
Revenue and Profits:
Net Sales:
121 Million
(Quarterly Results - Jun 2025)
Net Profit:
-17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.07%
0%
-14.07%
6 Months
-1.76%
0%
-1.76%
1 Year
-31.09%
0%
-31.09%
2 Years
-12.11%
0%
-12.11%
3 Years
-17.6%
0%
-17.6%
4 Years
-45.25%
0%
-45.25%
5 Years
-45.48%
0%
-45.48%
Lionco Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-20.24%
EBIT Growth (5y)
-196.08%
EBIT to Interest (avg)
-21.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.21
Tax Ratio
2.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.26%
ROE (avg)
2.40%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.49
EV to EBIT
-33.40
EV to EBITDA
-48.02
EV to Capital Employed
5.38
EV to Sales
10.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.10%
ROE (Latest)
-18.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
120.70
63.80
89.18%
Operating Profit (PBDIT) excl Other Income
-13.20
-18.70
29.41%
Interest
5.20
1.40
271.43%
Exceptional Items
-0.20
-0.30
33.33%
Consolidate Net Profit
-17.10
-24.40
29.92%
Operating Profit Margin (Excl OI)
-182.00%
-453.20%
27.12%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 89.18% vs 64.86% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 29.92% vs 47.75% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
375.00
191.80
95.52%
Operating Profit (PBDIT) excl Other Income
-67.00
-121.30
44.77%
Interest
27.40
3.80
621.05%
Exceptional Items
-22.30
-14.10
-58.16%
Consolidate Net Profit
-130.80
-151.50
13.66%
Operating Profit Margin (Excl OI)
-284.80%
-890.60%
60.58%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 95.52% vs -32.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 13.66% vs 22.66% in Dec 2023
About Lionco Pharmaceutical Group Co., Ltd. 
Lionco Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






